Wins and Deals at JP Morgan

January 13, 2014 | Luke Timmerman has a good roundup of the buzz and trends at the JP Morgan Healthcare Conference. The conference is still ongoing, but the winners so far appear to be Intercept Pharmaceuticals, a small New York company with a liver damage drug so successful that trials were stopped early; immuno-oncology as a field; rare diseases as targets; and Alnylam. Alnylam signed a deal with Genzyme to the tune of $700 million, and immediately used some of its new cash flow to buy RNAi technologies and Sirna Therapeutics from Merck. Xconomy